Announced details
Neurodegenerative diseases, including progressive supranuclear palsy (PSP)
Suppression of increases in NfL levels in cerebrospinal fluid. In the group switched from placebo to once-daily 400 mg dosing, NfL levels decreased from Week 24. In the group that continued once-daily 400 mg dosing for 48 weeks from baseline, NfL levels did not increase.
42 patients with PSP enrolled in the trial
The counterparty to which our company out-licensed OBP-601. The company is developing it for neurodegenerative diseases.
There will be no impact on the financial results for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
International medical journal Movement Disorders, August 2026 issue
| Item | Details |
|---|---|
| Names of Products / Services Covered | Censavudine (OBP-601/TPN-101) |
| Counterparty | Transposon Therapeutics, Inc |
| Relationship with the Company | The counterparty to which our company out-licensed OBP-601. The company is developing it for neurodegenerative diseases. |
| Applicable area | Neurodegenerative diseases, including progressive supranuclear palsy (PSP) |
| Quantitative Effects | Suppression of increases in NfL levels in cerebrospinal fluid. In the group switched from placebo to once-daily 400 mg dosing, NfL levels decreased from Week 24. In the group that continued once-daily 400 mg dosing for 48 weeks from baseline, NfL levels did not increase. |
| Usage history | 42 patients with PSP enrolled in the trial |
| Impact on Business Performance | There will be no impact on the financial results for the fiscal year ending December 2026. |
| Source | International medical journal Movement Disorders, August 2026 issue |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The results of the phase IIa clinical trial were published in the August 2026 issue of the international medical journal Movement Disorders.